Safety Assessment of Atomoxetine With MA IV Administration
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This is a study of 4 nontreatment seeking individuals who were MA-dependent and the safety
and tolerability of atomoxetine. This double-blind, placebo-controlled, within-subjects study
is to determine the safety and tolerability of atomoxetine.
MA abusing participants will undergo a 1-day outpatient screening and if it is safe for the
participants to proceed with the study they will participate in two inpatient components of
the study that will occur in the University of California Los Angeles (UCLA) General Clinical
Research Center (GCRC). The first inpatient stay will be 15 days, and the second will be a 9
days stay that includes drug administration and assessments. There will be at least a two
week interval between inpatient components. During the inpatient components participants will
receive alternating study drugs; atomoxetine or placebo and four sessions of IV MA
administration or saline.